Entremed, Inc., a clinical-stage pharmaceutical company, engages in developing therapeutics for the treatment of cancer and inflammatory diseases. It is developing primarily ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 is in Phase 1 studies in multiple myeloma and a multi-center, and Phase 2 studies in patients with platinum resistant ovarian cancer; and completed Phase 1 studies in patients with advanced solid tumors and leukemia. The company’s other drug candidates include MKC-1, which has completed Phase II clinical trials for cancer is an orally-active, small molecule, cell cycle inhibitor with in vitro and in vivo efficacy against a range of human solid tumor cell lines, including multi-drug resistant cell lines; ENMD-1198 that has completed a Phase I clinical trial in advanced cancers is an orally-active, anti-mitotic agent that induces cell cycle arrest and apoptosis in tumor cells; and Panzem (2-methoxyestradiol), an orally active compound for rheumatoid arthritis. Entremed, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Key Statistics